Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
José Luis González-Larriba, Pablo Maroto, Ignacio Durán, Julio Lambea, Luis Flores, Daniel Castellano & the Changing Group. (2017) The role of mTOR inhibition as second-line therapy in metastatic renal carcinoma: clinical evidence and current challenges. Expert Review of Anticancer Therapy 17:3, pages 217-226.
Read now
Read now
Eric Jonasch, James E. Signorovitch, Peggy L. Lin, Zhimei Liu, Ken Culver, Sumanta K. Pal, Jeffrey A. Scott & Nicholas J. Vogelzang. (2014) Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices. Current Medical Research and Opinion 30:10, pages 2041-2050.
Read now
Read now
Matteo Santoni, Michele De Tursi, Alessandra Felici, Giovanni Lo Re, Riccardo Ricotta, Enzo Maria Ruggeri, Roberto Sabbatini, Daniele Santini, Vanja Vaccaro & Michele Milella. (2013) Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives. Expert Review of Anticancer Therapy 13:6, pages 697-709.
Read now
Read now
Alessandra Felici, Emilio Bria, Giampaolo Tortora, Francesco Cognetti & Michele Milella. (2012) Sequential therapy in metastatic clear cell renal carcinoma: TKI–TKI vs TKI–mTOR. Expert Review of Anticancer Therapy 12:12, pages 1545-1557.
Read now
Read now
Giuseppe Procopio, Roberto Sabbatini, Camillo Porta, Elena Verzoni, Enzo Galligioni & Cinzia Ortega. (2012) Optimizing further treatment choices in short- and long-term responders to first-line therapy for patients with advanced renal cell carcinoma. Expert Review of Anticancer Therapy 12:8, pages 1089-1096.
Read now
Read now
Stephan Kruck, Jens Bedke, Markus A Kuczyk & Axel S Merseburger. (2012) Second-line systemic therapy for the treatment of metastatic renal cell cancer. Expert Review of Anticancer Therapy 12:6, pages 777-785.
Read now
Read now
Articles from other publishers (7)
Sumanta K Pal, James E Signorovitch, Nanxin Li, Miriam L Zichlin, Zhimei Liu, Sameer R Ghate, Jose Ricardo Perez & Nicholas J Vogelzang. (2017) Patterns of care among patients receiving sequential targeted therapies for advanced renal cell carcinoma: A retrospective chart review in the USA. International Journal of Urology 24:4, pages 272-278.
Crossref
Crossref
Nan Zhou, Fuding Lu, Cheng Liu, Kewei Xu, Jian Huang, Dexin Yu & Liangkuan Bi. (2016) IL-8 induces the epithelial-mesenchymal transition of renal cell carcinoma cells through the activation of AKT signaling. Oncology Letters 12:3, pages 1915-1920.
Crossref
Crossref
Patricia A. Creel. (2014) Optimizing Patient Adherence to Targeted Therapies in Renal Cell Carcinoma. Clinical Journal of Oncology Nursing 18:6, pages 694-700.
Crossref
Crossref
S. Pant, M. Saleh, J. Bendell, J.R. Infante, S. Jones, C.D. Kurkjian, K.M. Moore, J. Kazakin, G. Abbadessa, Y. Wang, Y. Chen, B. Schwartz & L.H. Camacho. (2014) A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors. Annals of Oncology 25:7, pages 1416-1421.
Crossref
Crossref
Iori Sakai, Hideaki Miyake & Masato Fujisawa. (2013) Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation. BJU International 112:2, pages E211-E220.
Crossref
Crossref
José Luís González Larriba, Enrique Espinosa, Icíar García Carbonero, Javier García-Donas, María López, Andrés Meana, Javier Puente & Joaquim Bellmunt. (2012) Sequential therapy in metastatic renal cell carcinoma: pre-clinical and clinical rationale for selecting a second- or subsequent-line therapy with a different mechanism of action. Cancer and Metastasis Reviews 31:S1, pages 11-17.
Crossref
Crossref
E. Calvo, B. Escudier, R.J. Motzer, S. Oudard, T.E. Hutson, C. Porta, S. Bracarda, V. Grünwald, J.A. Thompson, A. Ravaud, D. Kim, A. Panneerselvam, O. Anak & R.A. Figlin. (2012) Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. European Journal of Cancer 48:3, pages 333-339.
Crossref
Crossref